Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Obstetrics & Gynecology, advanced stage, chemotherapy, cisplatin, ovarian neoplasm, paclitaxel, SINGLE-AGENT CARBOPLATIN, RANDOMIZED TRIAL, STAGE-III, CHEMOTHERAPY, WOMEN, DOXORUBICIN, STANDARD, Antineoplastic Combined Chemotherapy Protocols, Canada, Cisplatin, Cyclophosphamide, Europe, Female, Follow-Up Studies, Humans, Longitudinal Studies, Neoplasm Staging, Ovarian Neoplasms, Paclitaxel, Randomized Controlled Trials as Topic, Survival Analysis, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Abstract:

Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin-paclitaxel regimen over cisplatin-cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.